FDA approves clinical use of cabozantinib (but not for prostate cancer, yet)

The U.S. Food & Drug Administration (FDA) has approved cabozantinib (brand name Cometriq™) for treatment of progressive, metastatic medullary thyroid cancer in the USA. … READ MORE …

Could we see cabozantinib (XL-184) approved some time next year?

According to a recent media release issued by Exelixis, cabozantinib (also known as XL-184) has shown effectiveness in a randomized, Phase III clinical trial in patients with advanced and metastatic medullary thyroid cancer. Obviously this is not metastatic prostate cancer, but these data look good enough for Exelixis to consider a submission for marketing approval. … READ MORE …